Humacyte Inc (HUMA)

$1.31 0.00 (N/A)
Market Cap 245.33M
Revenue (ttm) 0.00
Net Income (ttm) -148.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,131,600
Avg Vol 5,850,162
Day's Range N/A - N/A
Shares Out 187.27M
Stochastic %K 77%
Beta 1.90
Analysts Strong Sell
Price Target $7.86

Company Profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 313 9633
Address:
2525 East North Carolina Highway 54, Durham, United States
WallstreetTopExp
WallstreetTopExp Dec. 14 at 7:09 AM
$HUMA Descending Channel Breakout..✅ Expecting +150% Bullish Rally in the Coming days..📈 #Crypto #HUMA #HUMAUSDT
0 · Reply
bioman2024
bioman2024 Dec. 13 at 8:44 PM
$HUMA … what are current options for esophagus and trachea severe injury. Anyone?
1 · Reply
bioman2024
bioman2024 Dec. 13 at 8:43 PM
$HUMA …I would say there is strong potential to explore further regenerative solutions as symvess is in the process of proving itself out. DOW investment seems like a good further investment. imo
0 · Reply
bioman2024
bioman2024 Dec. 13 at 8:38 PM
$HUMA …Do you think the war dept only has interest in vascular injury? Overall, there's a significant potential for broader collaboration between Humacyte and the Department of Defense as they continue to focus on innovative medical solutions for military personnel.
0 · Reply
rubraquercus
rubraquercus Dec. 12 at 4:20 PM
$HUMA In case you don't know...The data strongly supports Humacyte's ongoing efforts to gain FDA approval for the hemodialysis indication, which would expand the use of its ATEV technology beyond its current approval for vascular trauma. Supplemental BLA Filing: Subject to the results of another ongoing Phase 3 trial (V012), Humacyte plans to submit a supplemental Biologics License Application (BLA) to the FDA in the second half of 2026 to add the AV access for hemodialysis indication. Market Potential: If approved, this ATEV could become a "game-changing" durable and clinically viable option for long-term hemodialysis access, addressing a large, underserved patient population.
1 · Reply
MarketPro
MarketPro Dec. 12 at 1:53 PM
$HUMA Appropriations probably not until January. NDAA will get a cloture vote on Monday - From Senate Democrat Schedule. “The filing deadline for first degree amendments in relation to S.1071, National Defense Authorization Act, is 4:00pm on Monday. At approximately 5:30pm, the Senate will vote on the motion to invoke cloture on the motion to concur in the House amendment to S.1071, NDAA.” This would actually be good timing as the release would come after tax-loss selling season.
1 · Reply
Whizz_123
Whizz_123 Dec. 12 at 2:13 AM
$HUMA My prediction is that both the Dialysis access and the peripheral arterial disease clinical trials will succeed.
2 · Reply
MarketPro
MarketPro Dec. 11 at 10:33 PM
$HUMA NATIONAL DEFENSE AUTHORIZATION ACT FOR FISCAL YEAR 2026 R E P O R T ON TO AUTHORIZE APPROPRIATIONS FOR FISCAL YEAR 2026 FOR MILITARY ACTIVITIES OF THE DEPARTMENT OF DEFENSE Biologic vascular repair for warfighters The committee notes that recent advancements in biologic vascular repair technology, successfully deployed to front-line hospitals in active conflict zones and austere environments, have resulted in Food and Drug Administration-approved innovations that present new opportunities to enhance care for servicemembers with vascular injuries sustained on the battlefield. These regenerative medicine technologies are off-the-shelf, universally implantable, demonstrate low susceptibility to infection, and can mitigate challenges associated with traditional vascular repair methods.
0 · Reply
MarketPro
MarketPro Dec. 11 at 10:31 PM
$HUMA Has the Senate passed the Defense Authorization Act? Saw the house passed it.... HUMA is about to have some sales happen....
1 · Reply
Buydadips
Buydadips Dec. 11 at 9:16 PM
$HUMA this pipeline is promising!
1 · Reply
Latest News on HUMA
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Nov 20, 2025, 8:00 AM EST - 23 days ago

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Nov 13, 2025, 8:00 AM EST - 4 weeks ago

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:21 PM EST - 4 weeks ago

Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:00 AM EST - 4 weeks ago

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Nov 10, 2025, 8:00 AM EST - 4 weeks ago

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Nov 6, 2025, 8:00 AM EST - 5 weeks ago

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Oct 30, 2025, 8:00 AM EDT - 6 weeks ago

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Oct 7, 2025, 9:00 AM EDT - 2 months ago

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Oct 6, 2025, 8:00 AM EDT - 2 months ago

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Sep 29, 2025, 8:00 AM EDT - 2 months ago

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Sep 18, 2025, 7:00 AM EDT - 3 months ago

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Sep 15, 2025, 7:00 AM EDT - 3 months ago

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress

Aug 12, 2025, 1:20 PM EDT - 4 months ago

Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress

Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 10:00 AM EDT - 4 months ago

Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 7:00 AM EDT - 4 months ago

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Aug 7, 2025, 8:00 AM EDT - 4 months ago

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Jul 23, 2025, 8:00 AM EDT - 5 months ago

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Jul 8, 2025, 8:00 AM EDT - 5 months ago

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Humacyte: Revenue Ramp From Symvess Incoming

Jun 11, 2025, 9:05 AM EDT - 6 months ago

Humacyte: Revenue Ramp From Symvess Incoming

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Jun 9, 2025, 8:00 AM EDT - 6 months ago

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Jun 2, 2025, 8:00 AM EDT - 6 months ago

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

May 19, 2025, 4:05 PM EDT - 7 months ago

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

May 13, 2025, 2:29 PM EDT - 7 months ago

Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 7:30 AM EDT - 7 months ago

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

May 9, 2025, 8:00 AM EDT - 7 months ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

Mar 28, 2025, 1:48 PM EDT - 9 months ago

Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Mar 28, 2025, 7:30 AM EDT - 9 months ago

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Mar 26, 2025, 8:00 AM EDT - 9 months ago

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Mar 25, 2025, 8:35 PM EDT - 9 months ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Mar 25, 2025, 4:01 PM EDT - 9 months ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Mar 10, 2025, 8:00 AM EDT - 9 months ago

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Trestle Bio Announces Research Collaboration with Humacyte

Mar 6, 2025, 8:00 AM EST - 10 months ago

Trestle Bio Announces Research Collaboration with Humacyte

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Mar 3, 2025, 8:00 AM EST - 10 months ago

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 4:05 PM EST - 10 months ago

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Feb 27, 2025, 8:00 AM EST - 10 months ago

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Feb 26, 2025, 8:00 AM EST - 10 months ago

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Feb 20, 2025, 1:35 PM EST - 10 months ago

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

Jan 21, 2025, 8:00 AM EST - 11 months ago

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Jan 17, 2025, 10:30 AM EST - 11 months ago

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

WallstreetTopExp
WallstreetTopExp Dec. 14 at 7:09 AM
$HUMA Descending Channel Breakout..✅ Expecting +150% Bullish Rally in the Coming days..📈 #Crypto #HUMA #HUMAUSDT
0 · Reply
bioman2024
bioman2024 Dec. 13 at 8:44 PM
$HUMA … what are current options for esophagus and trachea severe injury. Anyone?
1 · Reply
bioman2024
bioman2024 Dec. 13 at 8:43 PM
$HUMA …I would say there is strong potential to explore further regenerative solutions as symvess is in the process of proving itself out. DOW investment seems like a good further investment. imo
0 · Reply
bioman2024
bioman2024 Dec. 13 at 8:38 PM
$HUMA …Do you think the war dept only has interest in vascular injury? Overall, there's a significant potential for broader collaboration between Humacyte and the Department of Defense as they continue to focus on innovative medical solutions for military personnel.
0 · Reply
rubraquercus
rubraquercus Dec. 12 at 4:20 PM
$HUMA In case you don't know...The data strongly supports Humacyte's ongoing efforts to gain FDA approval for the hemodialysis indication, which would expand the use of its ATEV technology beyond its current approval for vascular trauma. Supplemental BLA Filing: Subject to the results of another ongoing Phase 3 trial (V012), Humacyte plans to submit a supplemental Biologics License Application (BLA) to the FDA in the second half of 2026 to add the AV access for hemodialysis indication. Market Potential: If approved, this ATEV could become a "game-changing" durable and clinically viable option for long-term hemodialysis access, addressing a large, underserved patient population.
1 · Reply
MarketPro
MarketPro Dec. 12 at 1:53 PM
$HUMA Appropriations probably not until January. NDAA will get a cloture vote on Monday - From Senate Democrat Schedule. “The filing deadline for first degree amendments in relation to S.1071, National Defense Authorization Act, is 4:00pm on Monday. At approximately 5:30pm, the Senate will vote on the motion to invoke cloture on the motion to concur in the House amendment to S.1071, NDAA.” This would actually be good timing as the release would come after tax-loss selling season.
1 · Reply
Whizz_123
Whizz_123 Dec. 12 at 2:13 AM
$HUMA My prediction is that both the Dialysis access and the peripheral arterial disease clinical trials will succeed.
2 · Reply
MarketPro
MarketPro Dec. 11 at 10:33 PM
$HUMA NATIONAL DEFENSE AUTHORIZATION ACT FOR FISCAL YEAR 2026 R E P O R T ON TO AUTHORIZE APPROPRIATIONS FOR FISCAL YEAR 2026 FOR MILITARY ACTIVITIES OF THE DEPARTMENT OF DEFENSE Biologic vascular repair for warfighters The committee notes that recent advancements in biologic vascular repair technology, successfully deployed to front-line hospitals in active conflict zones and austere environments, have resulted in Food and Drug Administration-approved innovations that present new opportunities to enhance care for servicemembers with vascular injuries sustained on the battlefield. These regenerative medicine technologies are off-the-shelf, universally implantable, demonstrate low susceptibility to infection, and can mitigate challenges associated with traditional vascular repair methods.
0 · Reply
MarketPro
MarketPro Dec. 11 at 10:31 PM
$HUMA Has the Senate passed the Defense Authorization Act? Saw the house passed it.... HUMA is about to have some sales happen....
1 · Reply
Buydadips
Buydadips Dec. 11 at 9:16 PM
$HUMA this pipeline is promising!
1 · Reply
TheYoungGeologist
TheYoungGeologist Dec. 11 at 7:57 PM
$HUMA feels like we're due for a push soon. Dialysis submittal still this quarter, right?
1 · Reply
stockwitsuser2449
stockwitsuser2449 Dec. 11 at 6:47 PM
$TERN give $HUMA a turn :)
0 · Reply
Musky49
Musky49 Dec. 11 at 4:55 PM
$HUMA Our days shall come.
1 · Reply
Rybod30
Rybod30 Dec. 11 at 4:15 PM
$HUMA The ask on this is stacked every day, tough to move from this level…
0 · Reply
APman
APman Dec. 11 at 3:56 PM
$HUMA https://uk.finance.yahoo.com/news/humacyte-huma-benchmark-remains-bullish-191204113.html
0 · Reply
Runmaster83
Runmaster83 Dec. 11 at 3:26 PM
$HUMA
1 · Reply
Diefreeandsell
Diefreeandsell Dec. 11 at 1:22 PM
$HUMA Careful shorts , coming back
0 · Reply
Buydadips
Buydadips Dec. 11 at 1:45 AM
$HUMA 14,000 shares traded at close?
0 · Reply
Ppbrain
Ppbrain Dec. 10 at 8:03 PM
$HUMA waiting for it to reach $5 be like
0 · Reply
Eldredk
Eldredk Dec. 10 at 6:37 PM
$HUMA current job openings at HUMA. Most posted or re-posted in the last 1-2 weeks.
1 · Reply
Runmaster83
Runmaster83 Dec. 10 at 5:52 PM
$HUMA Pump It!
0 · Reply
Scmin
Scmin Dec. 10 at 4:50 PM
$HUMA WOW the pumpers have been at it. They make it sound like we are already a multimillion dollar company. Laura can sell diddly. The whole market is up and we are red stuck below $1.30. We are a penny stock. No one is buying since Laura and Dougan sold Almost everything.
3 · Reply